Related Experiment Videos
Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma
A Ardizzoni1, M C Pennucci, B Castagneto
1Department of Medical Oncology, Ospedale S. Spirito of Casale Monferrato, Italy.
Abstract:
Fourteen patients with diffuse malignant pleural mesothelioma (DMPM) were enrolled in a Phase II study to assess activity and toxicity of the systemic administration of recombinant (r)-alpha-interferon (IFN)-2b. The IFN schedule was: 3 x 10(6) IU i.m. days 1-4, 6 x 10(6) IU days 5-8, 10 x 10(6) IU days 9-12; then IFN was administered at 10 x 10(6) IU 3 days/week. If grades II-III toxicity occurred, IFN dose was reduced and drug continued at the previous dose level. All patients were evaluated by CT scan. Only one patient was not evaluable for response and toxicity because of inadequate follow-up. Of 13 evaluable patients, we observed 1 objective response, 6 stable disease, and 6 failures (3 progressive disease and 3 early interruptions due to subjective toxicity). The median time to progression was 19 weeks, and the median overall survival was 62 weeks. Toxicity was mild: of 13 patients evaluable for toxicity we observed fever (9 patients), flu-like syndrome (3 patients), fatigue (4 patients), anorexia (2 patients), myelosuppression (3 patients), and muscle pain (1 patient). The results of this study indicate only marginal activity of r-alpha-IFN in the treatment of DMPM.
Insights
Recombinant alpha-interferon (IFN)-2b showed marginal activity in treating diffuse malignant pleural mesothelioma (DMPM). The study observed limited objective responses and mild toxicity in patients receiving systemic IFN-2b therapy.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Diffuse malignant pleural mesothelioma (DMPM) is an aggressive cancer with limited treatment options.
- Systemic therapies are crucial for managing DMPM, but novel agents are needed.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant alpha-interferon (IFN)-2b in patients with DMPM.
- To determine the objective response rate, time to progression, and overall survival in this patient cohort.
Main Methods:
- A Phase II study enrolled 14 patients with DMPM.
- Patients received escalating doses of recombinant alpha-interferon (IFN)-2b, followed by a maintenance dose.
- Response and toxicity were assessed using CT scans and clinical evaluation.
Main Results:
- Of 13 evaluable patients, 1 objective response, 6 stable disease, and 6 failures were observed.
- Median time to progression was 19 weeks, and median overall survival was 62 weeks.
- Reported toxicities were generally mild, including fever, flu-like symptoms, fatigue, anorexia, myelosuppression, and muscle pain.
Conclusions:
- Systemic administration of recombinant alpha-interferon (IFN)-2b demonstrated only marginal activity in the treatment of diffuse malignant pleural mesothelioma (DMPM).
- Further research may be needed to explore combination therapies or alternative treatment strategies for DMPM.